Cytodyn Inc. income statement CYDY

Annual Quarterly

It recorded a net loss of $42.7 million. Diluted earnings per share were -$0.03.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 May 31, 2026	FY 2025 May 31, 2025	FY 2024 May 31, 2024	FY 2023 May 31, 2023	FY 2022 May 31, 2022	FY 2021 May 31, 2021	FY 2020 May 31, 2020	FY 2019 May 31, 2019	FY 2018 May 31, 2018	FY 2017 May 31, 2017
Revenue	—	—	—	0 -100.0%	0	—	—	—	—	—
Cost of revenue	—	—	—	—	0	—	—	—	—	—
Gross profit	—	—	—	—	0	—	—	—	—	—
Research and development	—	—	7 +175.1%	3 -90.3%	27 -49.4%	53 +1.4%	53 +23.9%	42 +11.2%	38 +89.2%	20 +47.1%
Selling, general and administrative	7 +2.6%	7 -32.9%	11 -36.9%	17 -61.3%	44 +29.1%	34 +71.8%	20 +64.8%	12 +65.1%	7 +8.6%	7 -4.6%
Operating income	-39 -499.3%	10 +153.5%	-18 +55.5%	-41 +72.1%	-145 -39.0%	-105 -40.1%	-75 -33.7%	-56 -21.6%	-46 -68.0%	-27 -29.1%
Pretax income	-43 -1240.2%	4 +107.5%	-50 +37.6%	-80 +62.1%	-211 -19.5%	-176 -26.1%	-140 -137.1%	-59 -17.7%	-50 -94.7%	-26 -0.2%
Income tax	0	0	0	0	0	0	0 +100.0%	-3	0	0
Net income	-43 -1240.2%	4 +107.5%	-50 +37.6%	-80 +62.1%	-211 -19.5%	-176 -26.1%	-140 -149.1%	-56 -12.0%	-50 -94.7%	-26 -0.2%
Net income to common	-44 -2053.1%	2 +104.4%	-51 +40.8%	-87 +59.2%	-212	—	—	—	—	—
Basic EPS	-0.03	0.00 +100.0%	-0.05 +50.0%	-0.10 +67.7%	-0.31	—	—	—	—	—
Diluted EPS	-0.03	0.00 +100.0%	-0.05 +50.0%	-0.10 +67.7%	-0.31	—	—	—	—	—
Weighted average shares, basic	1,289 +6.9%	1,206 +24.4%	970 +15.9%	837 +23.6%	677	—	—	—	—	—
Weighted average shares, diluted	1,289 +3.7%	1,243 +28.2%	970 +15.9%	837 +23.6%	677	—	—	—	—	—
Other measures
Depreciation and amortization	0 -5.6%	0 -37.9%	0 -83.4%	0 -77.6%	1	—	2 +63.4%	1 +249.6%	0 -2.8%	0 +1.3%
EBITDA	-39 -498.4%	10 +153.7%	-18 +55.4%	-40 +72.1%	-145	—	-73 -33.0%	-55 -19.8%	-46 -69.0%	-27 -29.5%
Interest coverage	—	—	—	—	—	—	-4.10x	-16.86x	-7.75x	-44.60x
Margins
Gross margin	—	—	—	—	80.08%	—	—	—	—	—
Operating margin	—	—	—	—	-54,663.16%	—	—	—	—	—
Pretax margin	—	—	—	—	-79,255.64%	—	—	—	—	—
Profit margin	—	—	—	—	-79,255.64%	—	—	—	—	—
EBITDA margin	—	—	—	—	-54,369.55%	—	—	—	—	—
Effective tax rate	—	0.00%	—	—	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: CYDY (OTC)
Fiscal year ends: May 31
Incorporated in: DE
Headquarters: Vancouver, WA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1175680
Former names: CYTODYN INC (until Apr 13, 2016); REXRAY CORP (until Nov 12, 2003)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.